Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus

GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)

Study: GLP-1 drugs like semaglutide linked to lower amputation risk in diabetes patients with peripheral artery disease

A new study suggests that GLP-1 receptor agonists (like Ozempic and Wegovy) are associated with better outcomes in people with type 2 diabet

A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals - Nature Metabolism

Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption

This article discusses the rapid uptake and commercial success of GLP-1 receptor agonists for obesity management, highlighting their clinica

Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us

Triple hormone drug retatrutide shows promise for diabetes and weight loss in Lancet trial

A new triple hormone drug called retatrutide, which mimics GLP-1, GIP, and glucagon, has shown promising results in a Lancet-published trial